Our goal with hosting quarterly open threads is to give blog readers an opportunity to publicly raise comments or questions about GiveWell or related topics (in the comments section below). As always, you’re also welcome to email us at info@givewell.org or to request a call with GiveWell staff if you have feedback or questions you’d prefer to discuss privately. We’ll try to respond promptly to questions or comments.
You can view previous open threads here.
For many people, GiveWell is practically synonymous with our short list of top charities. But the amount of money we’ve sent to other organizations, doing other important work, has been increasing. In 2021, we made or recommended about $190 million in grants to non–top charity programs, like water treatment and malnutrition treatment, and in 2022, we set up the All Grants Fund specifically so donors could contribute to programs in this category.
We want to use this blog to give you more frequent, brief insights into these newer areas of our grantmaking before we publish our formal grant write-ups. Below we’ll discuss, in light detail, a program that’s well outside of our traditional wheelhouse, but that we think significantly improves children’s lives—treatment for clubfoot with an organization called MiracleFeet.
Our goal with hosting quarterly open threads is to give blog readers an opportunity to publicly raise comments or questions about GiveWell or related topics (in the comments section below). As always, you’re also welcome to email us at info@givewell.org or to request a call with GiveWell staff if you have feedback or questions you’d prefer to discuss privately. We’ll try to respond promptly to questions or comments.
You can view previous open threads here.
Since our founding in 2007, GiveWell has directed over $600 million to programs that aim to prevent malaria, a mosquito-borne disease that causes severe illness and death. Malaria is preventable and curable, yet it killed over 600,000 people in 2021—mostly young children in Africa.
Following the World Health Organization’s approval of the RTS,S/AS01 malaria vaccine (RTS,S) in late 2021, GiveWell directed $5 million to PATH to accelerate the roll out of the vaccine in certain areas of Ghana, Kenya, and Malawi. This grant aimed to enable these communities to gain access to the vaccine about a year earlier than they otherwise would, protecting hundreds of thousands of children from malaria.
Although we’re very excited about the potential of the RTS,S malaria vaccine to save lives, it isn’t a panacea. We still plan to support a range of malaria control interventions, including vaccines, nets, and antimalarial medicine.
In this post, we will:
We’re optimistic that GiveWell’s funds raised will continue to increase in the long run. Over the next few years, we believe our annual funds raised are more likely to stay relatively constant, due to a decrease in expected funding from our largest donor, Open Philanthropy, offset by an expected increase in funding from our other donors.
In November 2021, we wrote that we were anticipating rapid growth and aiming to influence $1 billion in 2025. Now, our best guess is that we’ll raise between $400 million and $800 million in 2025 (for comparison, we raised around $600 million in 2022). We now think it’s possible but unlikely that we’ll raise close to $1 billion in 2025, and we also think it’s possible but unlikely that our funds raised in 2025 will be substantially lower (e.g. around $300 million) than they were in 2022.
We’re excited about the impact we can have at any of those levels of funding, and we’ll be continuing to direct as much funding as we can raise to the most cost-effective opportunities we can find.
Our goal with hosting quarterly open threads is to give blog readers an opportunity to publicly raise comments or questions about GiveWell or related topics (in the comments section below). As always, you’re also welcome to email us at info@givewell.org or to request a call with GiveWell staff if you have feedback or questions you’d prefer to discuss privately. We’ll try to respond promptly to questions or comments.
You can view previous open threads here.